TORONTO (January 30, 2012) – Xagenic Inc., a start-up company created by Dr. Shana Kelley, in partnership with MaRS Innovation, today reached a significant milestone by successfully completing series A financing totaling $10 million.
The financing comes from sources from the private and public sector including CTI Life Sciences Fund L.P., Qiagen N.V. and the Ontario Capital Growth Corporation through its Emerging Technologies Fund. (more…)
Provincial Investment Supports Commercialization of Leading-Edge Molecular Diagnostic Screening Technology
TORONTO (July 26, 2011) — Xagenic Inc., one of MaRS Innovation’s (MI) portfolio spin-off companies, was awarded $1 million in funding by Ontario’s Ministry of Research and Innovation (MRI) through its Investment Accelerator Fund‐Life Sciences (IAF-LS) program.
Research and Innovation Minister Glen Murray made the announcement at MaRS Discovery District.
“Today’s announcement will go a long way in helping us to commercialize a technology that will ultimately shape the future of diagnostic testing — instead ...
MaRS Innovation to act as commercialization agent for York's life sciences and technology discoveries, leveraging new potential for York's existing $70 million in research initiatives
TORONTO, May 9, 2011 – York University has become the latest member of MaRS Innovation, the commercialization agent for many leading Toronto-based universities, hospitals and research institutes.
“York has become one of Canada’s fastest-growing centres for research and innovation,” said Stan Shapson, vice-president Research & Innovation at York University. “We typically get 10 to 20 discovery disclosures a ...
MaRS Innovation provided crucial commercialization funding to support research from The Hospital for Sick Children
MaRS Innovation (MI) and The Hospital for Sick Children (SickKids) have launched OtoSim Inc. to commercialize an otoscopy training system and process developed by two otolaryngologists at SickKids.
The new product, the OtoSim™ program and training device, is the first in a series of training systems directed at improving the accuracy of ear examinations. Using simulation-based training is part of a wider trend in medicine.
In otoscopy, healthcare professionals ...
Dr. John Rowlands’ X-ray Light Valve technology among the first TBRRI patents that MaRS Innovation will bring to market
January 26, 2011 (Thunder Bay, ON) – Today, MaRS Innovation welcomes Thunder Bay Regional Research Institute (TBRRI) as its newest member.
MaRS Innovation is an incorporated non-profit organization with an international, independent, industry-led Board of Directors. It is the commercialization agent for 16 member institutions that are leading Ontario life sciences and commercialization agents. Partners include the University of Toronto, Sunnybrook Health Sciences Centre, ...
Toronto’s (U of T)
TORONTO, ON and VANCOUVER, BC (November 30, 2009) - MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) are pleased to announce that they have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early-stage health-related discoveries.
“We are excited about our partnership with the CDRD as it provides an opportunity for the two organizations to augment each other’s strengths, and leverage resources to generate attractive packages for potential partners, thereby supporting both of our organizations’ ...
TORONTO (November 19, 2009) – In the drive to improve early detection and treatment of cancer, a pair of Toronto scientists has developed a unique technology that combines contrast agents with targeted, long-lasting nano-particles for use in multiple medical imaging platforms.
While contrast agents are routinely injected into patients to enhance the quality of medical images, different agents are currently required for various imaging modes (e.g. MRI, CT, PET) each with inherent strengths and limitations. By combining more than one contrast agent into a nano-particle ...
TORONTO (June 30, 2009) – MaRS Innovation (MI) and the University of Toronto (U of T) are pleased to announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers.
“There are 300 million diabetics worldwide, of which some 15 per cent develop troublesome foot ulcers. This wound healing technology is extremely exciting, making it an early commercialization opportunity that MaRS Innovation has identified as being a potential win for some ...